Aquestive Therapeutics
AQST
35 hedge funds and large institutions have $17M invested in Aquestive Therapeutics in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 10 closing their positions.
26% more capital invested
Capital invested by funds: $13.6M → $17M (+$3.47M)
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
0.02% more ownership
Funds ownership: 27.56% → 27.58% (+0.02%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 37 → 35 (-2)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$222K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$101K |
| 3 |
KAS
Kestra Advisory Services
Austin,
Texas
|
+$74.8K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$57.1K |
| 5 |
Renaissance Technologies
New York
|
+$48.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
-$457K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
-$104K |
| 3 |
Man Group
London,
United Kingdom
|
-$81.1K |
| 4 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
-$54.1K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$20.8K |
AQST Hedge Fund Activity: Q1 2023 in Review
35 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q1 2023, worth a combined $17M — up 26% from $13.6M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of AQST and 8 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was Millennium Management, adding an estimated $222K. The largest seller was Schonfeld Strategic Advisors, exiting entirely with an estimated $457K sold.
- 35 institutional investors held Aquestive Therapeutics (AQST) as of Q1 2023, down from 37 in Q4 2022.
- Funds reported $17M of Aquestive Therapeutics stock for Q1 2023, up 26% quarter-over-quarter.
- 8 funds opened new Aquestive Therapeutics positions in Q1 2023 and 10 closed out, a net change of -2 holders.
- The largest Aquestive Therapeutics buyer in Q1 2023 was Millennium Management, an estimated $222K added.
- The largest Aquestive Therapeutics seller in Q1 2023 was Schonfeld Strategic Advisors, an estimated $457K sold.
Based on aggregated 13F filings for Q1 2023.